Targeted therapy plus chemo for children with Ph+ or Ph-like B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests if adding a targeted drug (dasatinib or imatinib) to a chemotherapy combination with blinatumomab works better for children and young adults with a specific genetic form of B-cell acute lymphoblastic leukemia. The goal is to see if this approach can improve treatment outcomes for patients with Philadelphia chromosome-positive or ABL-class Ph-like B-ALL.
Summary written for real people, not researchers, by Clin2.
Who can take part
- This trial is for children, teens, and young adults (ages 1 to 22, or up to 46 at some hospitals) with a specific type of B-cell acute lymphoblastic leukemia (B-ALL) that has a Philadelphia chromosome or a similar genetic change called ABL-class Ph-like.
- Patients must have recently started standard chemotherapy (induction therapy) and have not received more than 14 days of targeted therapy (dasatinib or imatinib).
- Participants need to have good kidney, liver, and heart function based on recent tests.
- Patients cannot have certain health conditions, such as Down syndrome, uncontrolled infections, or a history of serious heart rhythm problems.
- Females who are pregnant or breastfeeding, and any patient who is not willing to use effective birth control during treatment, cannot join the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
This trial tests two new drug combinations for a specific type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) that has a genetic change called KMT2A-rearrangement. The goal is to help patients who are at higher risk of their cancer coming back after initial treatment.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
Hear when a new B Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.